Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06536283 · ClinicalTrials.gov registry record
Opiophobia in Postsurgical Adults With Cancer
A clinical trial of Opiophobia, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06536283: Active study of Opiophobia, sponsored by M.D. Anderson Cancer Center.
NCT06536283 is a study of Opiophobia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06536283, a study of Opiophobia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn how people who underwent surgery feel about their prescribed opioid medication after they leave the hospital.
Primary Outcome
Use of opioids among a population of adults who underwent surgery for cancer.
Conditions Studied
Interventions
- OTHER 13-item Barriers Questionnaire (BQ-13)
- OTHER Four-item Medication Adherence Questionnaire
- OTHER 14-item Hospital Anxiety and Depression Scale (HADS)
Study Locations (1)
Texas
- The Univerisity of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT06536283 still lists
NCT06536283 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 1 condition, with Opiophobia appearing as the primary indexed condition, and to 3 interventions - of which 13-item Barriers Questionnaire (BQ-13) is the first listed.
NCT06536283 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06536283 about?
NCT06536283 is a clinical study titled "Opiophobia in Postsurgical Adults With Cancer". To learn how people who underwent surgery feel about their prescribed opioid medication after they leave the hospital.
What is the current status of trial NCT06536283?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2024-09-16. Estimated completion is 2026-12-31.
What conditions does trial NCT06536283 study?
This clinical trial studies the following conditions: Opiophobia.
What interventions are being tested in trial NCT06536283?
The interventions under investigation include: 13-item Barriers Questionnaire (BQ-13) (OTHER), Four-item Medication Adherence Questionnaire (OTHER), 14-item Hospital Anxiety and Depression Scale (HADS) (OTHER).
Who is sponsoring clinical trial NCT06536283?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06536283 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI